19th Nov 2013 10:56
LONDON (Alliance News) - EKF Diagnostics Holdings said Tuesday it is progressing well with the development of a Point of Care platform for Acute Kidney Injury, with testing on clinical samples set to commence in early 2014.
Testing is the next phase in the development which has been undertaken with Carclo Diagnostic Solutions. The platform is being developed as an alternative to standard lateral flow testing as a device to detect Acute Kidney Injury.
The firm said that testing and an assay based on Carclo's micropoc-pro platform should be complete by mid-2014.
Share in EKF were up 1.57% at 33.0 pence per share Tuesday morning. Carclo shares were trading down 4.89% at 331 pence per share.
By Alice Attwood; [email protected]; @AliceAtAlliance
Copyright © 2013 Alliance News Limited. All Rights Reserved.
Related Shares:
CarcloEkf Diagnostics